Bonum Health Announces New Prescription Education Resources via Telehealth App
Trxade Group, Inc. (NASDAQ: MEDS) an integrated drug procurement, delivery and healthcare platform announces new app feature within it’s Telehealth Application, Bonum Health. New Patient Prescription Education development includes a new searchable medication appendix to providing patients with visual identification and written information regarding any current medication or prescription.
Within each patient’s profile, the resource features continue to evolve to better educate patients on their health. The patient can query a drug search within the app to identify pertinent information such as food and drug interactions and more regarding the therapies they have been prescribed. This feature not only intends to improve health literacy of their prescribed therapies but also improve overall health outcomes. Medications and formulations of prescriptions are listed along with a visual medication identifier guide for typical shape and color.
As a supplement to additional medication questions, the application allows patients to research further by allowing for web searches as well as social media postings, inquiries and discussions. The aim of our Telehealth service is to assist every patient by providing well trained physicians, patient education, and a wealth of resources to ensure good health and compliance.
About Trxade Group, Inc. Headquartered in Tampa, Florida, Trxade Group, Inc. (Nasdaq: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy delivery capabilities using DelivMeds app. For additional information, please visit us at http://www.trxade.com http://www.delivmeds.com, and http://www.bonumhealth.com.
Leave a ReplyWant to join the discussion?
Feel free to contribute!